Ulla M Forssen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ulla M Forssen has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Amy H Herring
Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, North Carolina, USA
1 shared publicationDavid A Savitz
Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, North Carolina, USA
1 shared publicationJ Michael Wright
Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, North Carolina, USA
1 shared publicationJ. M. Micallef
Worldwide Epidemiology, GlaxoSmithKline, Stockley Park, Middlesex, UK
1 shared publicationJ. M. Pimenta
Worldwide Epidemiology, GlaxoSmithKline, Stockley Park, Middlesex, UK
1 shared publication- Jeanne M. Pimenta
BioMarin (UK) Limited, London, UK
1 shared publication
Latest Publications
- Open Access
- 11 April 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 86
The high comorbidity burden of the hepatitis C virus infected population in the United States
Chronic hepatitis C (HCV) disease can be complicated with comorbid conditions that may impact treatment eligibility and outcomes. The aim of the study was to systematically review comorbidities and symptoms in an HCV infected population, specifically assessing comorbidities associated with HCV anti-viral treatment and disease, as well as comparing comorbidities between an HCV infected and uninfected control population.
- 11 April 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 86
Open AccessThe high comorbidity burden of the hepatitis C virus infected population in the United States
Chronic hepatitis C (HCV) disease can be complicated with comorbid conditions that may impact treatment eligibility and outcomes. The aim of the study was to systematically review comorbidities and symptoms in an HCV infected population, specifically assessing comorbidities associated with HCV anti-viral treatment and disease, as well as comparing comorbidities between an HCV infected and uninfected control population.
- 26 August 2010
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 18 (1) , 1-7
Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review
Summary. Thrombocytopenia (TCP) is a haematological condition known to occur in chronically infected hepatitis C (HCV) patients and may interfere with diagnostic procedures, such as liver biopsy, because of risk of bleeding. It may also exclude patients from effective antiviral treatment. We conducted a systematic literature review of articles and conference abstracts, to assess the prevalence of TCP among those with HCV and to describe demographics, liver disease stage and treatment characteristics of these patients. Studies of individuals with confirmed chronic HCV infection were included in the review if the study had a clear definition of thrombocytopenia and a sample size of at least 50 subjects. The final selection included 27 studies (21 articles and six abstracts). The definitions of thrombocytopenia varied between studies and were based either on platelet counts, with threshold levels ranging between ≤100 × 109 and ≤180 × 109/L, or on criteria set in haematological guidelines. The prevalence of TCP ranged from 0.16% to 45.4% and more than half of the studies reported a TCP prevalence of 24% or more. Because of the different TCP definitions, heterogeneity in study design and insufficient data on study characteristics such as age, gender, HCV treatment rates and disease severity an overall summary estimate of TCP prevalence among patients with HCV was not feasible. However, the relatively large prevalence in the majority of the studies suggests that there may be a substantial number of HCV patients at risk of bleeding complications and reduced likelihood of successful HCV antiviral treatment.
- 26 August 2010
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 18 (1) , 1-7
Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review
Summary. Thrombocytopenia (TCP) is a haematological condition known to occur in chronically infected hepatitis C (HCV) patients and may interfere with diagnostic procedures, such as liver biopsy, because of risk of bleeding. It may also exclude patients from effective antiviral treatment. We conducted a systematic literature review of articles and conference abstracts, to assess the prevalence of TCP among those with HCV and to describe demographics, liver disease stage and treatment characteristics of these patients. Studies of individuals with confirmed chronic HCV infection were included in the review if the study had a clear definition of thrombocytopenia and a sample size of at least 50 subjects. The final selection included 27 studies (21 articles and six abstracts). The definitions of thrombocytopenia varied between studies and were based either on platelet counts, with threshold levels ranging between ≤100 × 109 and ≤180 × 109/L, or on criteria set in haematological guidelines. The prevalence of TCP ranged from 0.16% to 45.4% and more than half of the studies reported a TCP prevalence of 24% or more. Because of the different TCP definitions, heterogeneity in study design and insufficient data on study characteristics such as age, gender, HCV treatment rates and disease severity an overall summary estimate of TCP prevalence among patients with HCV was not feasible. However, the relatively large prevalence in the majority of the studies suggests that there may be a substantial number of HCV patients at risk of bleeding complications and reduced likelihood of successful HCV antiviral treatment.
- 1 October 2008
- Published by Springer Nature in Journal of Exposure Science & Environmental Epidemiology
- Vol. 19 (6) , 593-602
Variability and predictors of changes in water use during pregnancy
Disinfection by-products in tap water have been found in some studies to be associated with adverse pregnancy outcomes, but little is known about how water use and consumption might change during early pregnancy. Estimating water-related activities only at one time during pregnancy could easily lead to exposure misclassification. To evaluate changes in water use among pregnant women, we used data from a large epidemiologic study in which 1990 women were interviewed around 9 and 20 weeks' gestation. The water variables that were examined included ingestion of cold and hot tap water as well as of bottled water, showering and bathing. Changes were detected between early and mid-pregnancy for ingested cold tap water and showering. Thirty-three percent of the subjects changed cold-water ingestion by ≥1.0 liters/day and 44% changed their time showering by ≥35 min per week during this period. Increases in cold tap water intake were associated with age >35 years, income <$40,000, and non-Hispanic white ethnicity. We also found that the proportion of the total variation due to within-subject variability was 62% for hot tap water ingestion but only 35% for showering and ~50% for cold tap water, bottled water and bathing. Limited resources in epidemiologic studies often require a decision between collecting data for a large number of people or collecting multiple measurements for a smaller number of people. The results in this study will be useful to researchers who need to determine where to invest their effort when assessing water-related exposures and should help in evaluation of previously performed studies.
- 1 October 2008
- Published by Springer Nature in Journal of Exposure Science & Environmental Epidemiology
- Vol. 19 (6) , 593-602
Variability and predictors of changes in water use during pregnancy
Disinfection by-products in tap water have been found in some studies to be associated with adverse pregnancy outcomes, but little is known about how water use and consumption might change during early pregnancy. Estimating water-related activities only at one time during pregnancy could easily lead to exposure misclassification. To evaluate changes in water use among pregnant women, we used data from a large epidemiologic study in which 1990 women were interviewed around 9 and 20 weeks' gestation. The water variables that were examined included ingestion of cold and hot tap water as well as of bottled water, showering and bathing. Changes were detected between early and mid-pregnancy for ingested cold tap water and showering. Thirty-three percent of the subjects changed cold-water ingestion by ≥1.0 liters/day and 44% changed their time showering by ≥35 min per week during this period. Increases in cold tap water intake were associated with age >35 years, income <$40,000, and non-Hispanic white ethnicity. We also found that the proportion of the total variation due to within-subject variability was 62% for hot tap water ingestion but only 35% for showering and ~50% for cold tap water, bottled water and bathing. Limited resources in epidemiologic studies often require a decision between collecting data for a large number of people or collecting multiple measurements for a smaller number of people. The results in this study will be useful to researchers who need to determine where to invest their effort when assessing water-related exposures and should help in evaluation of previously performed studies.